Aprea Therapeutics, Inc. (APRE)

NASDAQ: APRE · Delayed Price · USD
2.50
-0.14 (-5.30%)
At close: Jan 18, 2022 4:00 PM
2.52
0.02 (0.80%)
After-hours:Jan 18, 2022 6:42 PM EST
Market Cap53.66M
Revenue (ttm)n/a
Net Income (ttm)-44.76M
Shares Out21.47M
EPS (ttm)-2.11
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume313,436
Open2.56
Previous Close2.64
Day's Range2.50 - 2.60
52-Week Range2.48 - 8.46
Beta-0.16
AnalystsHold
Price Target4.33 (+73.2%)
Earnings DateNov 4, 2021

About APRE

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung ca...

IndustryBiotechnology
IPO DateOct 3, 2019
Employees11
Stock ExchangeNASDAQ
Ticker SymbolAPRE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for APRE stock is "Hold." The 12-month stock price forecast is 4.33, which is an increase of 73.20% from the latest price.

Price Target
$4.33
(73.20% upside)
Analyst Consensus: Hold

News

Aprea Therapeutics, Inc. (APRE) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Aprea Therapeutics, Inc. (APRE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analyst...

4 days ago - Zacks Investment Research

Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Mai...

BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) --  Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant...

1 month ago - GlobeNewsWire

Got $5 to Spend on Penny Stocks? Check These 4 Out

Got $5 to spend on penny stocks? Take a look at these four for your watchlist The post Got $5 to Spend on Penny Stocks?

Other symbols:ABUSMARKMETX
1 month ago - PennyStocks

Aprea (APRE) Reports FDA Removal of Clinical Hold on Study

The FDA removes its clinical hold on Aprea Therapeutics' (APRE) clinical study evaluating eprenetapopt combination study in lymphoid malignancies.

1 month ago - Zacks Investment Research

FDA Lifts Clinical Hold On Aprea's Eprenetapopt Trial In Myeloid Malignancies

The FDA removed the full clinical hold on Aprea Therapeutics Inc's (NASDAQ: APRE) trial evaluating the combination of eprenetapopt, with acalabrutinib or with venetoclax and rituximab in lymphoid malign...

1 month ago - Benzinga

Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on Business Operations

BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mut...

2 months ago - GlobeNewsWire

Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd American Society of Hematolog...

BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant ...

2 months ago - GlobeNewsWire

Aprea Therapeutics Stock Jumps After Eprenetapopt Combo Data Presentation At ESMO

Aprea Therapeutics Inc (NASDAQ: APRE) presented data at the European Society of Medical Oncology (ESMO) Congress 2021 from its Phase 1/2 trial in advanced solid tumors.  The trial is evaluating the safe...

3 months ago - Benzinga

Aprea Therapeutics Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advanced Solid Tumors at ESMO Cong...

BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mu...

3 months ago - GlobeNewsWire

Is the Options Market Predicting a Spike in Aprea Therapeutics (APRE) Stock?

Investors need to pay close attention to Aprea Therapeutics (APRE) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

Best Penny Stocks To Buy? 5 To Watch This Week With Biotech Catalysts

Penny stocks with important dates to know this week. The post Best Penny Stocks To Buy?

Other symbols:CAPRCFMSSPPIVSTM
3 months ago - PennyStocks

Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on Business Operations

BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mut...

5 months ago - GlobeNewsWire

Aprea Therapeutics Drops After FDA Clinical Hold On Another Blood Cancer Study

After instituting a partial clinical hold on Aprea Therapeutics Inc's (NASDAQ: APRE) myeloid malignancies program, the FDA has placed a clinical hold on Aprea's lymphoid malignancy study.  The trial is ...

5 months ago - Benzinga

Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program

BOSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant ...

5 months ago - GlobeNewsWire

Aprea Therapeutics Stock Drops On FDA Clinical Hold On Eprenetapopt Myeloid Malignancy Trials

The FDA has instituted a partial clinical hold on Aprea Therapeutics Inc's (NASDAQ: APRE) clinical trials of eprenetapopt (APR-246) combined with azacitidine in its myeloid malignancy programs.  Approxi...

5 months ago - Benzinga

Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs

BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant ...

5 months ago - GlobeNewsWire

Aprea Stock Pops As Eprenetapopt Combo Regime Shows 58% Relapse-Free Survival, 79% Overall Survival At 1-Year Post-Tr...

Aprea Therapeutics Inc (NASDAQ: APRE) has announced results from its Phase 2 trial evaluating eprenetapopt with azacitidine for post-transplant maintenance therapy in patients with TP53 mutant myelodysp...

5 months ago - Benzinga

Implied Volatility Surging for Aprea (APRE) Stock Options

Investors need to pay close attention to Aprea (APRE) stock based on the movements in the options market lately.

7 months ago - Zacks Investment Research

Aprea (APRE) Stock Rises as Leukemia Triplet Meets Study Goal

Aprea (APRE) announces that treatment with a combination regimen of its pipeline candidate, eprenetapopt, achieves 37% complete response rate in acute myeloid leukemia patients.

7 months ago - Zacks Investment Research

Karolinska Development's portfolio company Aprea Therapeutics lead candidate drug eprenetapopt reaches primary effica...

STOCKHOLM, SWEDEN – June 17, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Aprea Therapeutics has reported positive outcomes in an ongoing Phase 1/2...

7 months ago - GlobeNewsWire

Best Biotech Penny Stocks to Buy? Here's 3 That Are Well Funded

Looking for well-funded biotech penny stocks? Check these 3 small-caps out The post Best Biotech Penny Stocks to Buy?

Other symbols:ITRMPOAI
7 months ago - PennyStocks

Why Kindred Biosciences, Aprea, Catabasis And Inhibikase Are Moving Today

Kindred Biosciences, Inc. (NASDAQ: KIN), Aprea Therapeutics, Inc. (NASDAQ: APRE), Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) and Inhibikase Therapeutics, Inc. (NASDAQ: IKT) are among the biggest bio...

Other symbols:IKT
7 months ago - Benzinga

APRE Stock: The Big Leukemia Study News That Has Aprea Therapeutics Skyrocketing Today

Aprea Therapeutics (APRE) stock is seeing major gains on Wednesday after revealing results from a recent Phase 1/2 trial. The post APRE Stock: The Big Leukemia Study News That Has Aprea Therapeutics Sky...

7 months ago - InvestorPlace

Aprea Therapeutics Stock Is Trading Higher As Eprenetapopt Triplet Therapy Achieves 37% CR Rate In Leukemia Patients

Aprea Therapeutics Inc (NASDAQ: APRE) has announced that the Phase 1/2 trial evaluating eprenetapopt in acute myeloid leukemia (AML) has met the pre-specified primary efficacy endpoint of complete remis...

7 months ago - Benzinga

Why Aprea Therapeutics Shares Are Surging Today

Aprea Therapeutics Inc (NASDAQ:APRE) shares are trading higher by 46% at $7.07 after the company announced the Phase 1/2 trial of eprenetapopt with venetoclax and azacitidine in TP53 mutant AML met the ...

7 months ago - Benzinga